文献速递消化系统肿瘤

高危剂量舒尼替尼每周一次或每两周一次给药在难治性实体瘤患者中的I期剂量递增研究

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
PubMed 文献 · J Clin Oncol · 2018-12-26

该I期研究采用标准3+3设计,对69例难治性晚期实体瘤患者(以结直肠癌为主,占42%)给予每周一次或每两周一次高危剂量舒尼替尼,起始剂量为每周一次200 mg,按100 mg递增。每周一次最大耐受剂量为300 mg,每两周一次为700 mg,后者最高血药浓度达标准剂量的18倍;最常见不良事件为疲乏(81%)、恶心(48%)和厌食(33%),仅疲乏(6%)为≥5%患者中的3/4级治疗相关不良事件。作者认为每两周一次700 mg可考虑为最优方案,但其初步抗肿瘤活性尚需进一步临床评估。

要点

  • 每周一次最大耐受剂量为300 mg,每两周一次为700 mg,后者最高血药浓度较标准剂量高18倍。
  • 最常见不良事件为疲乏(81%)、恶心(48%)和厌食(33%),仅疲乏(6%)为≥5%患者中的3/4级治疗相关不良事件。
  • 63%患者获显著临床获益,30%患者无进展生存期达5个月或以上。

核心结论

  • 每周一次300 mg或每两周一次700 mg舒尼替尼给药可行,耐受性与每日给药相当。
  • 每两周一次700 mg因达到最高最高血药浓度可考虑为最优方案。
  • 该替代方案在经重度治疗患者中显示有前景的初步抗肿瘤活性,需进一步临床评估,并可能最终提示酪氨酸激酶抑制剂的类别特征。

研究设计与样本

  • I期剂量递增研究,采用标准3+3设计。
  • 纳入标准治疗难治的晚期癌症患者,共69例接受治疗,以结直肠癌为主(42%)。
  • 舒尼替尼起始剂量为每周一次200 mg,按100 mg递增;每周一次和每两周一次队列在最大耐受剂量水平各额外纳入10例患者。
  • 主要终点为安全性和耐受性。

主要发现

  • 最大耐受剂量为每周一次300 mg和每两周一次700 mg。
  • 每周一次300 mg和每两周一次700 mg的最高血药浓度分别较标准剂量高9倍和18倍。
  • 最常见不良事件为疲乏(81%)、恶心(48%)和厌食(33%)。
  • 在5%或以上患者中唯一的3/4级治疗相关不良事件为疲乏(6%)。
  • 63%患者有显著临床获益,30%患者无进展生存期达5个月或以上。

临床怎么用

  • 作者认为每两周一次700 mg可考虑为最优方案,因达到最高最高血药浓度。
  • 作者认为该替代方案的初步抗肿瘤活性需进一步临床评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in patients with refractory solid malignancies was conducted. PATIENTS AND METHODS: Patients with advanced cancer refractory to standard treatment were eligible. With use of a standard 3 + 3 phase I design, patients received escalating doses of sunitinib, in 100 mg increments, starting at 200 mg once weekly. In both the once weekly and once every 2 weeks cohorts, 10 more patients were included at the maximum tolerated dose level. Primary end points were safety and tolerability. RESULTS: Sixty-nine patients with advanced cancer, predominantly colorectal cancer (42%), were treated with this alternative dosing regimen. Maximum tolerated dose was established at 300 mg once weekly and 700 mg once every 2 weeks, resulting in nine- and 18-fold higher maximum plasma concentrations compared with standard dose, respectively. Treatment was well tolerated, with fatigue (81%), nausea (48%), and anorexia (33%) being the most frequent adverse events. The only grade 3 or 4 treatment-related adverse event in 5% or more of patients was fatigue (6%). Sixty-three percent of patients had significant clinical benefit, with a 30% progression-free survival of 5 months or more. CONCLUSION: Sunitinib administered once weekly at 300 mg or once every 2 weeks at 700 mg is feasible, with comparable tolerability as daily administration. Administration of 700 mg once every 2 weeks can be considered as the most optimal schedule because of the highest maximum plasma concentration being reached. The promising preliminary antitumor activity of this alternative schedule in heavily pretreated patients warrants further clinical evaluation and might ultimately indicate a class characteristic of tyrosine kinase inhibitors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rovithi M, Gerritse SL, Honeywell RJ, et al. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. J Clin Oncol. 2018. PMID: 30586316. doi:10.1200/JCO.18.00725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。